MDNA — Medicenna Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$91.75m
- CA$71.45m
Annual cashflow statement for Medicenna Therapeutics, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.3 | -22.6 | -10 | -25.5 | -11.8 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 1.26 | 0.799 | -5.02 | 8.46 | -6.05 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.68 | -1.84 | 2.41 | 0.741 | 1.31 |
| Change in Accounts Receivable | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -15.3 | -23.6 | -12.7 | -16.3 | -16.5 |
| Capital Expenditures | — | — | — | — | -0.033 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 5.01 | 10.1 | 0 | — | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 5.01 | 10.1 | 0 | — | -0.033 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 18.3 | 3.88 | 24.8 | 0 | 23.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.68 | -9.84 | 13.1 | -16.6 | 7.86 |